AgingResearch.NewsJoin free

T-Maximum Pharmaceutical

CompanyChina

T-Maximum Pharmaceutical develops one asset, in phase 2 (MT027 in brain metastases from breast cancer). Mostly cell therapy acting on CD276; based in China.

1
Asset
Furthest stage
Phase 2
0
Trials
1
Signal

Pipeline

1

  • MT027

    Allogeneic CAR-T cells target B7-H3-expressing cancer cells for destruction.

    Phase 2, Cell therapy, CD276, brain metastases from breast cancer, brain metastases from lung cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Signals1

Intelligence